394 related articles for article (PubMed ID: 25152272)
1. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis.
Sherrard LJ; Tunney MM; Elborn JS
Lancet; 2014 Aug; 384(9944):703-13. PubMed ID: 25152272
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
[TBL] [Abstract][Full Text] [Related]
3. The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis.
Sibley CD; Parkins MD; Rabin HR; Surette MG
Curr Opin Investig Drugs; 2009 Aug; 10(8):787-94. PubMed ID: 19649923
[TBL] [Abstract][Full Text] [Related]
4. The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection.
McCaughey G; Gilpin D; Elborn J; Tunney MM
Expert Rev Respir Med; 2013 Aug; 7(4):385-96. PubMed ID: 23964628
[TBL] [Abstract][Full Text] [Related]
5. Microbiome in cystic fibrosis: Shaping polymicrobial interactions for advances in antibiotic therapy.
Lopes SP; Azevedo NF; Pereira MO
Crit Rev Microbiol; 2015; 41(3):353-65. PubMed ID: 24645634
[TBL] [Abstract][Full Text] [Related]
6. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.
Fodor AA; Klem ER; Gilpin DF; Elborn JS; Boucher RC; Tunney MM; Wolfgang MC
PLoS One; 2012; 7(9):e45001. PubMed ID: 23049765
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection.
Caverly LJ; Zhao J; LiPuma JJ
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S31-8. PubMed ID: 26335953
[TBL] [Abstract][Full Text] [Related]
8. The cystic fibrosis airway microbiome.
Rabin HR; Surette MG
Curr Opin Pulm Med; 2012 Nov; 18(6):622-7. PubMed ID: 22965275
[TBL] [Abstract][Full Text] [Related]
9. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.
Waters V; Ratjen F
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):807-19. PubMed ID: 17140357
[TBL] [Abstract][Full Text] [Related]
10. The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis.
Frayman KB; Armstrong DS; Carzino R; Ferkol TW; Grimwood K; Storch GA; Teo SM; Wylie KM; Ranganathan SC
Thorax; 2017 Dec; 72(12):1104-1112. PubMed ID: 28280235
[TBL] [Abstract][Full Text] [Related]
11. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
12. Update on antibiotics for infection control in cystic fibrosis.
Kirkby S; Novak K; McCoy K
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):967-80. PubMed ID: 19803706
[TBL] [Abstract][Full Text] [Related]
13. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic use in cystic fibrosis.
Eisenberg JD
Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
[TBL] [Abstract][Full Text] [Related]
15. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.
Waters VJ; Kidd TJ; Canton R; Ekkelenkamp MB; Johansen HK; LiPuma JJ; Bell SC; Elborn JS; Flume PA; VanDevanter DR; Gilligan P;
Clin Infect Dis; 2019 Oct; 69(10):1812-1816. PubMed ID: 31056660
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for antimicrobial stewardship in cystic fibrosis?
Waters VJ; Ratjen FA
Ann Am Thorac Soc; 2014 Sep; 11(7):1116-9. PubMed ID: 25102101
[TBL] [Abstract][Full Text] [Related]
17. "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.
Gilligan PH; Downey DG; Elborn JS; Flume PA; Funk S; Gilpin D; Kidd TJ; McCaughan J; Millar BC; Murphy PG; Rendall JC; Tunney MM; Moore JE
J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29875191
[TBL] [Abstract][Full Text] [Related]
18. Inhaled antimicrobial therapy - barriers to effective treatment.
Weers J
Adv Drug Deliv Rev; 2015 May; 85():24-43. PubMed ID: 25193067
[TBL] [Abstract][Full Text] [Related]
19. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
20. The cystic fibrosis lung microbiome.
Surette MG
Ann Am Thorac Soc; 2014 Jan; 11 Suppl 1():S61-5. PubMed ID: 24437409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
